Introduction
Venous thromboembolism (VTE) is a frequent complication and a major cause of death in patients with cancer [1, 2] . Large population-based studies and disease registry surveys have revealed that around 20% of patients with VTE have active cancer [3] [4] [5] . In these patients, VTE is not only associated with shortened survival, but it also has an impact on quality of life because of chronic residual symptoms and anxiety caused by fear of recurrence [6] . However, there is also evidence that bleeding to death is a major complication for some cancer patients receiving anticoagulants to manage their VTE.
Based on randomized clinical trials and meta-analyses [7] [8] [9] [10] [11] , current guidelines of antithrombotic therapy recommend that cancer patients with VTE receive initial therapy with low-molecular-weight heparin (LMWH), fondaparinux or unfractionated heparin, followed by long-term therapy with LMWH rather than vitamin K antagonists (VKAs) [1, [12] [13] [14] [15] . The use of LMWH during the first 3 months has been established by clinical trials with a high level of evidence, but there is no consensus regarding the optimal duration of anticoagulation beyond the third month. In the absence of data, the decision regarding the termination or continuation of anticoagulant therapy beyond the first 3 months is largely based on individual evaluation of the benefit : risk ratio. However, most randomized clinical trials were underpowered to assess fatal VTE or fatal bleeding, and a substantial proportion of patients were excluded because of a high risk of bleeding or terminal stages of the malignancy. Consequently, real-world data reporting has become increasingly relevant.
Large administrative databases, primarily from healthcare insurance claims, are impressive in terms of the quantity of data, but have limitations in terms of the accuracy, consistency and completeness of coding and reporting [16] . Even if prescribed-medication data are sometimes available, association with clinical outcomes is missing. The RIETE (Registro Informatizado Enfermedad Trombo Emb olica) registry provides real-world estimates using the natural history of patients with symptomatic, objectively proven deep vein thrombosis (DVT) or pulmonary embolism (PE) [17] . This review article provides an overview of the published literature in cancer patients with VTE, mostly using data from RIETE.
Rationale, design and methodology of the RIETE registry RIETE is an ongoing, prospective multicenter observational study of patients with acute VTE. The registry was originally started in Spain in 2001 with the goal of gathering a large sample of patients with VTE, with specific attention given to those excluded from randomized trials of anticoagulant therapy. The aim was to understand their common presentation, management pattern and outcomes, as well as factors associated with better or worse patient outcomes. The hope was also to use the hypothesis-generating findings to help design new randomized clinical studies. The platform was translated into English from 2006 and the network expanded to other participating centers. RIETE is registered at Clinicaltrials.gov (NCT: 02832245). Detailed information about participating centers is also available at the registry website: https://www.riete.org/.
At each participating site, patients are screened by the site investigators and checked for eligibility. All patients had objectively confirmed acute symptomatic or asymptomatic VTE. More recently, RIETE also started to enroll patients with superficial vein thrombosis, splanchnic vein thrombosis, retinal vein thrombosis and cerebral vein thrombosis. At each participating center, every attempt is made to enroll consecutive patients and RIETE investigators are committed, by contract agreement, to enroll consecutive patients. Periodic audits of the sites have confirmed consecutiveness. No duplicate entries are permitted and patients who are enrolled in blinded treatment trials are ineligible.
The number of variables has been progressively increasing over the years. Recently, depending on the events, ancillary tests, therapies and follow-up duration, each patient may be represented by up to 1000 variables filled out. Data quality is electronically monitored on a weekly basis. In the case of identification of several inconsistencies from any enrolling center, a full audit of all the data from that center is performed. In addition, trained staff make periodic visits to participating centers and compare the information in a randomly selected sample of patients entered by the site investigators.
Case-fatality rates of VTE recurrences and major bleeding
The advantages of anticoagulant therapy must be weighed against the risk of adverse events, primarily bleeding. Moreover, when weighing the risks and benefits of anticoagulation in an individual cancer patient, in addition to considering the absolute risk of VTE recurrences and major bleeding, the consequences associated with each of these outcomes need to be considered. In this sense, the case-fatality rate (CFR) of recurrent VTE and major bleeding, defined as the proportion of patients who died as a consequence of these conditions, could provide useful information to balance the risks and benefits of anticoagulant therapy.
A systematic study of 13 prospective cohort studies and 56 randomized trials assessed the CFR of recurrent VTE and major bleeding during anticoagulation and recurrent VTE after anticoagulation [18] . The authors found that the CFRs of recurrent VTE and major bleeding were similar during the initial period of VTE treatment (3 or 6 months), but the CFR of recurrent VTE decreased after completion of the initial period of anticoagulation. However, most of the patients in that review did not have cancer and estimates came from heterogeneous trial and cohort populations.
To provide reliable estimates of the CFR of recurrent VTE and major bleeding in cancer patients with VTE in real-life clinical practice, we studied 9112 patients receiving anticoagulation for a mean of 7.8 AE 0.6 months [19] . Among 4498 patients initially presenting with PE, 185 developed VTE recurrences (46 died of PE) and 186 had major bleeding (42 died of bleeding). Among 4614 cancer patients initially presenting with DVT, there were 217 VTE recurrences (20 died of PE) and 51 major bleeds (51 died of bleeding). Thus, although cancer patients with PE more likely had a recurrence as PE, those presenting with DVT most likely had a recurrence as DVT. Interestingly, the highest incidence of both VTE recurrences and major bleeding was observed in the first weeks of therapy and progressively decreased afterwards. Our data also confirmed that although initially similar, the CFR of recurrent VTE progressively decreased during anticoagulation, whereas the CFR of major bleeding barely varied over time. The CFR of major bleeding exceeded the CFR of recurrent VTE after the first month of therapy, leading to a higher cumulative mortality from this cause.
Fatal PE and fatal bleeding in cancer patients with VTE
In January 2006, 14 391 patients with VTE were enrolled in RIETE, of whom 2945 (20%) had active cancer [20] . In patients with cancer, the rate of fatal PE during the first 3 months was 2.6% and fatal bleeding was 1.0%. These frequencies were much higher than in VTE patients without cancer (1.4% and 0.3%, respectively). Some years later we assessed the time-course and clinical characteristics of cancer patients with VTE who died of PE or bleeding [21] . There were 10 962 patients (5740 with PE, 5222 with DVT alone), and during the 12-month follow-up, 239 (2.17%) died of PE and 170 (1.55%) had fatal bleeding. After disseminated cancer, PE was the second most frequent cause of death, followed by respiratory insufficiency, infection and then bleeding. Thus, fatal PE was the most common cause of preventable death, accounting for 5.4% of deaths (239 of 4406 deaths), and bleeding accounted for 3.9% (171 deaths). Interestingly, one in every 10 patients with fatal PE (11%) or fatal bleeding (8.2%) was under 50 years old, and one in every four (24% and 29%, respectively) did not have metastases (Table 1) . This is important because it is particularly critical that fatalities in cancer patients with relatively good prognosis are avoided. Interestingly, 44% of the fatal PEs and 36% of the fatal bleeds developed shortly after surgery or immobilization (and thus could have been prevented).
Fatal PE occurred early after the initial event and mostly during the first month of anticoagulant therapy, before reaching close to maximum at 3 months, after which very few cases occurred [21] . In contrast, cases of fatal bleeding occurred throughout the 12 months, with just less than half of cases within the first month of treatment. As it could be expected, most cases of fatal PE and fatal bleeding occurred while on anticoagulant therapy but a higher proportion (1/11) of fatal bleeds than fatal PEs (1/25) occurred after discontinuing anticoagulation.
For patients initially presenting with PE, subsequent PE was the most prominent cause of death and three times more common than bleeding, whereas in patients with DVT alone at baseline, bleeding was as common as infection as a cause of death and over three times more common than PE [21] . The lower risk of dying from PE in patients initially presenting with DVT can be attributed to the fact that DVT patients most likely recurred as DVT. The daily doses of LMWH therapy did not appear to account for differences in outcomes between patients presenting with DVT alone or with PE, and the rate of fatal bleeding was similar over time [21] . Thus, our data suggest that a key factor in determining the intensity and duration of anticoagulant therapy should be the initial presentation of VTE.
The influence of cancer site on outcome
A number of variables (including advanced cancer stage, concomitant therapies and co-morbidities) may have an influence on outcomes during anticoagulation for VTE [3, 5] . However, the influence of the cancer site on outcome has not been consistently studied yet. In another study by our group, we compared the rates of VTE recurrences and major bleeding during anticoagulant therapy in patients with breast (n = 938), prostate (n = 629), colorectal (n = 1189) or lung (n = 1191) cancer [22] . Of these, 55% had metastases (42%, 36%, 53% and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of VTE recurrences was similar to the rate of major bleeding in patients with breast (5.6 vs. 4.1 events per 100 patient-years) or colorectal cancer (10 vs. 12 per 100 patient-years). In contrast, in patients with prostate cancer the rate of VTE recurrences was half the rate of major bleeding (6.9 vs. 13 events per 100 patient-years), whereas in those with lung cancer, the rate of VTE recurrences was over 2-fold higher than the rate of major bleeding (27 vs. 11 per 100 patient-years).
For patients with breast, prostate or colorectal cancer, the rate of VTE recurrences was half that of major bleeds during the first month of therapy. Also, patients with lung cancer suffered a 2-fold higher rate of VTE recurrences than major bleeds, both during and beyond the first 30 days of therapy. Thus, our findings revealed that the rate of VTE recurrences and major bleeding during anticoagulation largely varies according to the location of cancer. These findings suggest the development of cancerspecific anticoagulant strategies is an area for further research.
Incidental PE
Current guidelines on antithrombotic therapy suggest treating patients with incidentally found PE similarly to patients with symptomatic PE [1] . Van der Hulle et al. evaluated the outcome in 926 cancer patients with incidental PE from 11 cohorts, and found a high risk of symptomatic PE events during follow-up, particularly when left untreated [23] . However, the follow-up period was limited to only 6 months, and there was no information on the quality of anticoagulation, the consequences of PE, the frequency and severity of bleeding events or the outcomes after discontinuing anticoagulant therapy. In another RIETE study on 715 cancer patients with incidental PE [24] , patients were followed-up for a mean of 235 days during anticoagulation, and then 117 days after discontinuing anticoagulation. The rate of major bleeding during therapy was 3-fold higher than the rate of symptomatic PE (10.1 vs. 3.17 events per 100 patient-years, respectively), and the rate of fatal bleeding was 4-fold higher than the rate of fatal PE (2.66 vs. 0.66 deaths per 100 patient-years). After discontinuing anticoagulant therapy, the rate of major bleeding was lower than the rate of symptomatic PE (3.00 vs. 8.37 events per 100 patientyears), but there were no differences in the rate of fatal events (one death each). Unfortunately, we were unable to identify independent predictors for symptomatic PE during follow-up.
Splanchnic vein thrombosis
The role of anticoagulant therapy in patients with splanchnic vein thrombosis (SVT) is uncertain, given the absence of randomized trials and the increased risk of bleeding in patients who often also have liver cirrhosis or cancer. Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic SVT and suggest no anticoagulation in those with incidental SVT [1] , but supporting evidence for these recommendations is limited by the small size of the studies.
Of 604 patients recruited in a large international cohort of patients with SVT, 136 (22.5%) had solid cancer [25] . Anticoagulation was administered to 465 (77%) patients (mean, 13.9 months) and the incidence rates during anticoagulation in the whole cohort were 3.9 per 100 patientyears for major bleeding and 5.6 for thrombotic events. After treatment discontinuation, rates were 1.0 per 100 patient-years and 10.5, respectively. We recently reported our experience of 521 patients with SVT (45% had cancer) [26] . Many of them were at increased risk of bleeding, because of liver cirrhosis, gastroduodenal ulcer, esophageal varices, cancer, renal insufficiency, thrombocytopenia or anemia. The majority of patients in our cohort (93%) did receive anticoagulation, often at therapeutic doses and for over 6 months in up to 50% of cases. During the course of anticoagulation, the mortality associated with major bleeding outweighed the mortality associated with VTE recurrences, particularly during the first month. Interestingly, patients with incidental SVT had a 2-fold higher risk of symptomatic VTE recurrences than and a similar risk of major bleeding to those with symptomatic SVT. Hence, the risk/benefit ratio of anticoagulant therapy in patients with SVT should be better evaluated in future studies.
Anticoagulant therapy in real-life practice
A number of studies and registries conducted from around the world report suboptimal adherence to guideline-recommended anticoagulant therapy even during the acute treatment period [27] . Reasons for this poor performance are unknown. In another RIETE study on 6345 cancer patients with VTE, 66% received long-term LMWH therapy and 24% switched to vitamin K antagonists (VKA) [28] . Compared with those receiving VKA, patients on long-term LMWH therapy were younger, less had more DVT recurrences and fewer major bleeds than those treated with ≥ 150 IU kg À1 day À1 , but also had fewer fatal PEs. This is an unexpected finding, which might not be explained by these patients probably being sicker, because any difference in their baseline characteristics is likely to have disappeared after propensity score matching.
Optimal duration of anticoagulant therapy
The optimal duration of anticoagulation in cancer patients with VTE is unknown. In the literature, no studies have yet consistently assessed the efficacy and safety of anticoagulant therapy beyond the first 6 months. In the absence of data, the decision regarding the termination or continuation of anticoagulant therapy beyond the first 3 or 6 months is largely based on individual evaluation of the benefit : risk ratio and patients' preferences. The comparative risk of fatal PE (after anticoagulant withdrawal) or bleeding (as a result of continued anticoagulant therapy) needs to be determined. Meanwhile, published cohort studies and registries conducted from around the world have uniformly reported suboptimal adherence to guideline-recommended therapy [30] [31] [32] [33] .
Direct oral anticoagulants (DOACs)
The Hokusai VTE-cancer trial compared the efficacy and safety of edoxaban for 6-12 months vs. dalteparin in 1046 cancer patients with VTE [34] . During the course of anticoagulation, patients receiving edoxaban had a lower rate of DVT recurrences (hazard ratio [HR], 0.56; 95% CI, 0.32-0.97), a similar rate of PE recurrences (HR, 1.0; 95% CI, 0.59-1.69), a higher rate of major bleeding (HR, 1.77; 95% CI, 1.03-3.04) and a non-significantly higher rate of non-major but clinically relevant bleeding (HR, 1.38; 95% CI, 0.98-1.94). Similar findings (fewer VTE recurrences and more major bleeds) were found in a trial that compared rivaroxaban for 6 months vs. dalteparin, although the study was not sufficiently powered to allow definitive conclusions [35] . Most bleeding events in patients with DOACs in both trials occurred in the gastrointestinal tract and in patients with gastrointestinal cancers. There also is some real-world experience on the use of DOACs in cancer patients with VTE. In the Mayo Thrombophilia Clinic DOACs registry, there were no differences in the rates of VTE recurrences or major bleeding in patients receiving rivaroxaban or enoxaparin for 3-12 months [36] .
Limitations of RIETE
Our studies have a number of potential limitations, which need to be addressed. First, RIETE is an observational registry and our findings are hypothesis generating. There is no external adjudication of the events, which are reported by the treating physicians. The dosing and regimen of prescribed drugs can vary according to country, center, underlying diseases and site of cancer. Finally, a variety of practitioners entered data into the registry, which may lend itself to potential inaccuracies in the data being reported.
Conclusions
Current guidelines for anticoagulant therapy do not so far suggest any form of differentiated approach to cancer patients with VTE. Our findings provide some insights into what factors may be used to guide physicians in adapting recommended anticoagulant regimens to the individual patient, as oncologists are increasingly doing with cancer treatments (Table 2) . For instance, patients presenting with DVT alone might benefit from curtailing treatment intensity as anticoagulant therapy progresses. The site of cancer also needs to be considered, because the rate of VTE recurrences during therapy was half the rate of major bleeding in patients with prostate cancer, and over 2-fold higher in those with lung cancer. In patients with incidental PE or splanchnic vein thrombosis, we should be more cautious before prescribing anticoagulant therapy. The optimal duration of anticoagulant therapy is unknown.
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